Free Trial

Oruka Therapeutics Q1 2023 Earnings Report

Oruka Therapeutics logo
$9.91 -0.24 (-2.36%)
As of 03/3/2025 04:00 PM Eastern

Oruka Therapeutics EPS Results

Actual EPS
-$12.96
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Oruka Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Oruka Therapeutics Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Oruka Therapeutics Earnings Headlines

Leaked Trump video exposes his secret stocks
Ten investments secretly owned by Trump’s biggest backers. Ten investments intrinsically tied to the policies Trump will put in place. Ten investments with the potential to return 10x or more… but only if you act right now.
Stifel Nicolaus Remains a Buy on Oruka Therapeutics (ORKA)
See More Oruka Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oruka Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oruka Therapeutics and other key companies, straight to your email.

About Oruka Therapeutics

Oruka Therapeutics (NASDAQ:ORKA) is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

View Oruka Therapeutics Profile

More Earnings Resources from MarketBeat